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Targeting glutamine uptake in AML
Nathalie Jacque and Didier Bouscary
Cancer cells require nutrients and energy to 
adapt to increased biosynthetic activity and depend on 
mitochondrial oxidative phosphorylation (OXPHOS) 
and glycolysis. Whereas they exhibit a pronounced 
Warburg effect, their TCA cycle remains intact and 
becomes more dependent on glutamine metabolism 
through glutaminolysis[1]. Besides this role, intracellular 
glutamine is also essential for mTORC1 activation by 
leucine[2]. Many upstream signals regulate mTORC1 
activation. Among them, a major process is the 
availability of leucine, which is required to activate 
the Rag (for Ras-related GTPases) proteins that enable 
the proper localization of mTORC1 at the lysosome 
surface close to its activator Rheb[3]. Leucine uptake 
into the cells is regulated by the bidirectional transporter 
SLC7A5/3A2, in exchange for glutamine. The level of 
leucine thereby depends on the intracellular glutamine 
concentrations, which is mainly mediated by the high 
affinity transporter SLC1A5. Thus, the cellular uptake 
and subsequent rapid efflux of glutamine in the presence 
of leucine make glutamine availability a limiting step for 
the activation of mTORC1. MTORC1 positively regulates 
protein translation through phosphorylation of protein 
S6 Kinase (P70S6K) and eukaryotic initiation factor 4E 
(eIF4E)-binding protein 1 (4E-BP1). Protein synthesis is 
controlled by the translational repressor 4E-BP1 whose 
phosphorylation at serine 65 is required to initiate the 
formation of the translation initiation complex. 
The dependence of acute myeloid leukemia (AML) 
cells to glutamine is little studied. In a recent work, we 
have tested the effects of glutamine depletion in AML 
cells[4]: leukemic cells are sensitive to glutamine removal 
leading to mTORC1 inhibition and apoptosis. The drug 
L-asparaginase (L-ase) also inhibits mTORC1 activity 
in AML cells, suppresses protein synthesis and induces 
apoptosis. The anti-leukemic effects of the two clinically 
available forms of L-ase, E Coli L-ase (Kidrolase®) and 
E. Chrysanthemi L-ase (Erwiniase®) are not mediated 
by the asparaginase activity of the enzyme. L-ases have 
also a glutaminase activity and transform extracellular 
glutamine into glutamate. Both L-ases induce dose and 
time-dependent mTORC1-inhibition which correlates 
with extra-cellular glutamine depletion[4]. Downstream 
of mTORC1, L-ase suppresses 4E-BP1 phosphorylation 
and inhibits [S35] methionine incorporation into newly 
synthesized proteins, indicative of global protein 
synthesis inhibition. Finally, we showed that L-ase 
treatment acts through inhibition of leucine entry into the 
cells by depleting intracellular glutamine, thus preventing 
mTORC1 activation by Rheb at the lysosomal surface[4]. 
Overall, those data open the way for new therapies 
targeting glutamine uptake in AML. L-ase has been 
previously tested in AML. A randomized study that 
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Figure: AML cells are addicted to glutamine. Limiting glutamine uptake by L-asparaginase, glutamine removal or knockdown of the 
glutamine transporter SLC1A5 inhibits mTORC1 activity and protein synthesis by limiting leucine uptake by the bidirectional transporter 
SLC7A5/3A2. Resulting intracellular leucine depletion limits the proper localization of mTORC1 close to its direct activator, the Rheb 
kinase, at the lysosomal surface. Limiting glutamine uptake may also exert anti-leukemic effects through inhibition of glutaminolysis, the 
key gatekeeper of which is the enzyme glutaminase (GLS) which catalyzes the hydrolysis of glutamine to glutamate. Some GLS isoforms 
can be specifically inhibited by compound 968 and BPTES.
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compared the effects of high dose cytarabine with or 
without E. Coli L-ase in refractory/relapsed AML in 
adults revealed a significantly increased CR rate with 
the association (40% vs. 24%)[5]. Blast cells from 
the M1, M4 and M5 FAB subtypes may display an in 
vitro sensitivity to L-ase very close to that of acute 
lymphoblastic leukemia cells. Further preclinical studies 
are thus warranted to characterize new chemotherapeutic 
combinations in association to L-ase in AML.
We also identified potential mechanisms of 
resistance to L-ase treatment in AML. L-ase upregulates 
glutamine synthase (GS) protein expression and this 
process may limit the L-ase-induced anti-leukemic 
activity in AML. GS inhibition by the L-methionine-
sulfoximine (MSO) may increase the sensitivity of 
AML cells to L-ase as described in ALL. Moreover, 
L-ase triggers an autophagic process, probably resulting 
from mTORC1 inhibition (mTORC1 inhibits autophagy 
by controlling the activity of Atg1/ULK and ATG13 
proteins). Knockdown of either ATG5 or Beclin, two 
proteins controlling autophagy, increase apoptosis 
in L-ase-treated AML cells. The future testing of a 
combination of autophagy inhibitors and L-ase is thus 
warranted in AML.
Another therapeutic strategy to exploit AML 
glutamine dependence may be to target the glutamine 
transporters. We showed that the knockdown of the high 
affinity transporter SLC1A5 has strong anti-leukemic 
effects in vitro and inhibits tumor formation in an AML 
mouse xenotransplantation model[4]. However, SLC1A5 
inhibition was not efficient in all AML cell lines, 
indicating that other glutamine transporters may control 
glutamine-mediated mTORC1 activation in AML[4].
We only address here the role of glutamine uptake 
by AML cells on the control of mTORC1 activation. 
Studies are needed to examine its role in mitochondrial 
anaplerosis through glutaminolysis. The key gatekeeper 
of glutaminolysis is the enzyme glutaminase (GLS) 
which catalyzes the hydrolysis of glutamine to glutamate, 
which is then converted to the TCA cycle intermediate 
α-ketoglutarate (α-KG). Two different forms of GLS exist: 
the liver-type glutaminase (LGA, coded by the GLS2 
gene) and the glutaminase 1 (GLS gene) which exists as 
two splice variants: the longer form called kidney-type 
glutaminase (KGA) and the shorter called glutaminase C 
(GAC)[6]. The two GLS1 isoforms are up-regulated in 
cancers. Two inhibitors of GLS1 have been characterized: 
the compound 968, a specific allosteric inhibitor of GAC, 
and BPTES that potently inhibits both GLS isoforms. 
Although several studies showed anti-tumoral effects of 
the two inhibitors in many cancers[7], the targeting of 
glutaminolysis in AML is still to be proved. Recently, it 
has been suggested that BPTES could suppress the growth 
of primary AML cells with IDH mutations[8].
To conclude, through inhibition of mTORC1 
activity and/or through suppression of the mitochondrial 
TCA cycle, glutamine metabolism constitutes an 
appealing target for treating this particularly poor 
prognosis disease. 
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